Genetic Immunity Inc. is developing a DNA-based, state-of-the-art transdermal immunotherapy platform to treat viral and cancer diseases. Our lead product candidate, DermaVir™ HIV vaccines, is a pDNA/PEIm nanomedicine that steps into a Phase III Clinical Trial.